Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) shares traded down 3.5% on Friday . The stock traded as low as $42.31 and last traded at $43.08, with a volume of 494,368 shares traded. The stock had previously closed at $44.63.

Several research analysts have recently weighed in on the company. Brean Capital reaffirmed a “hold” rating on shares of Pacira Pharmaceuticals in a research note on Friday. TheStreet downgraded Pacira Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, May 2nd. BMO Capital Markets reiterated a “sell” rating and set a $36.00 price target on shares of Pacira Pharmaceuticals in a research report on Friday. Mizuho started coverage on Pacira Pharmaceuticals in a research report on Tuesday, April 19th. They set a “buy” rating and a $79.00 price target for the company. Finally, Wedbush reiterated an “outperform” rating and set a $113.00 price target on shares of Pacira Pharmaceuticals in a research report on Wednesday, May 4th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and seven have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $72.73.

The firm has a 50-day moving average price of $37.38 and a 200-day moving average price of $49.70. The firm’s market capitalization is $1.62 billion.

Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its quarterly earnings data on Thursday, August 4th. The company reported $0.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.16. The firm had revenue of $69.60 million for the quarter, compared to analyst estimates of $67.80 million. The business’s revenue for the quarter was up 17.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.20 earnings per share. On average, equities analysts predict that Pacira Pharmaceuticals Inc. will post $0.30 earnings per share for the current year.

In other news, VP Lauren Bullaro Riker sold 938 shares of the business’s stock in a transaction on Tuesday, June 7th. The stock was sold at an average price of $47.66, for a total value of $44,705.08. Following the completion of the transaction, the vice president now directly owns 5,945 shares of the company’s stock, valued at $283,338.70. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Mark A. Kronenfeld sold 900 shares of the business’s stock in a transaction on Monday, June 6th. The stock was sold at an average price of $46.95, for a total value of $42,255.00. Following the completion of the transaction, the director now directly owns 2,950 shares of the company’s stock, valued at $138,502.50. The disclosure for this sale can be found here.

Other institutional investors recently added to or reduced their stakes in the company. Stephens Investment Management Group LLC increased its stake in shares of Pacira Pharmaceuticals by 10.0% in the fourth quarter. Stephens Investment Management Group LLC now owns 540,687 shares of the company’s stock worth $41,519,000 after buying an additional 49,018 shares in the last quarter. Morgan Stanley increased its stake in shares of Pacira Pharmaceuticals by 28.7% in the fourth quarter. Morgan Stanley now owns 120,614 shares of the company’s stock worth $9,261,000 after buying an additional 26,865 shares in the last quarter. California Public Employees Retirement System increased its stake in shares of Pacira Pharmaceuticals by 182.5% in the fourth quarter. California Public Employees Retirement System now owns 77,400 shares of the company’s stock worth $5,944,000 after buying an additional 50,000 shares in the last quarter. New York State Common Retirement Fund increased its stake in shares of Pacira Pharmaceuticals by 38.1% in the fourth quarter. New York State Common Retirement Fund now owns 57,483 shares of the company’s stock worth $4,414,000 after buying an additional 15,867 shares in the last quarter. Finally, Rhumbline Advisers increased its stake in shares of Pacira Pharmaceuticals by 8.0% in the fourth quarter. Rhumbline Advisers now owns 42,471 shares of the company’s stock worth $3,261,000 after buying an additional 3,160 shares in the last quarter.

Pacira Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.